Tag Archives: Keay Nakae

Chardan Capital Believes Emergent Biosolutions (NYSE: EBS) Still Has Room to Grow

In a report issued on April 24, Keay Nakae from Chardan Capital reiterated a Buy rating on Emergent Biosolutions (EBS – Research Report), with a price target of $71.00. The company’s shares closed last Friday at $73.30, close to its

Chardan Capital Thinks Exicure’s Stock is Going to Recover

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Exicure (XCUR – Research Report) today and set a price target of $5.00. The company’s shares closed last Thursday at $1.44, close to its 52-week low of $0.96. According to

Chardan Capital Remains a Buy on ProQR (PRQR)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on ProQR (PRQR – Research Report), with a price target of $25.00. The company’s shares closed last Tuesday at $5.49, close to its 52-week low of

Ocugen (OCGN) Receives a Buy from Chardan Capital

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Ocugen (OCGN – Research Report), with a price target of $2.00. The company’s shares closed last Friday at $0.30, close to its 52-week low of

BiomX (PHGE) Gets a Buy Rating from Chardan Capital

Chardan Capital analyst Keay Nakae reiterated a Buy rating on BiomX (PHGE – Research Report) today and set a price target of $28.00. The company’s shares closed last Monday at $7.04. According to TipRanks.com, Nakae is a 1-star analyst with

Chardan Capital Sticks to Their Buy Rating for OncoCyte (OCX)

Chardan Capital analyst Keay Nakae reiterated a Buy rating on OncoCyte (OCX – Research Report) today and set a price target of $7.75. The company’s shares closed last Monday at $1.99, close to its 52-week low of $1.50. According to